Investing.com - Aslan Pharma ADR reported on Tuesday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of -0.12 on revenue of 0.00. Analysts polled by Investing.com anticipated EPS of -0.105 on revenue of 0.00.
Aslan Pharma ADR shares are down 13.19% from the beginning of the year and are trading at 2.730 , down-from-52-week-high.They are under-performing the Nikkei 225 which is up 2.56% from the start of the year.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by J&J on April 20, who reported EPS of 2.59 on revenue of 22.32B, compared to forecasts EPS of 2.34 on revenue of 21.98B.
Pfizer had beat expectations on May 4 with first quarter EPS of 0.93 on revenue of 14.58B, compared to forecast for EPS of 0.7759 on revenue of 13.65B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar